程序性死亡分子-1及其配体在非小细胞肺癌中的治疗进展

Progression of PD-1/PD-L1 in non-small cell lung cancer therapy

肺癌的传统治疗不尽人意,迫切需要探索新的治疗方法来打破这一瓶颈局面。免疫治疗是一种高特异性,低毒的新型治疗手段,其中阻断PD-1/PD-L1通路是最具有前景的治疗方向之一,目前大量研究报道PD-1和PD-L1抑制剂在晚期非小细胞肺癌治疗中取得显著疗效。然而PD-1/PD-L1抑制剂作为单药治疗或与其他抗肿瘤治疗联合在非小细胞肺癌中存在争议,本文将PD-1/PD-L1抑制剂在非小细胞肺癌中的治疗现状及最新进展进行综述。

The traditional treatment of lung cancer is not satisfactory, so it is urgent to explore new therapy to break the bottleneck. Immunotherapy is a new treatment with low toxicity and high specificity. Suppressing the PD-I/PD-L1 pathway is considered as one of the most promising treatments. A number of studies reported that blockade of PD-1 and its ligand PD-L1 achieved favorable outcomes for advanced non-small cell lung cancer patients. Nonetheless, the anti-PD-1/PD-L1 antibody as monotherapy or in combination with other antineoplastic therapy in non-small cell lung cancer remains controversial. In this article, we reviewes the current state of research and advancement of PD-I/PD-L1 in the treatment of non-small cell lung cancer.